

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PegBio Co., Ltd.

派格生物醫藥(杭州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2565)

INSIDE INFORMATION

ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION APPLICATION BY THE COMPANY

This announcement is made by PegBio Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”).

Reference is made to the announcement of the Company dated November 28, 2025 (the “**Announcement**”) in relation to the application for the proposed implementation of H Share full circulation (“**H Share Full Circulation**”) by the Company. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that the Company has received a filing notice dated March 26, 2026 (the “**Filing Notice**”) issued by the CSRC in respect of the implementation of the H Share Full Circulation. According to the Filing Notice, the filing made by the Company with the CSRC in respect of the implementation of the H Share Full Circulation for an aggregate of 101,702,051 Unlisted Shares has been completed. If the Conversion of the Shares is not completed within 12 months from the date of the Filing Notice, and the Company still intends to proceed, the Company shall update the filing materials with the CSRC. The Company will apply to the Stock Exchange for the listing of, and permission to deal in, such H Shares on the Main Board of the Stock Exchange.

As at the date of this announcement, the details of the implementation plan of the H Share Full Circulation have not been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation in compliance with the requirements under the Listing Rules and/or the Inside Information Provisions as and when appropriate.

The H Share Full Circulation is subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
PegBio Co., Ltd.
Michael Min XU
*Chairman of the Board, Executive Director
and General Manager*

Hong Kong, April 9, 2026

As of the date of this announcement, the Board of the Company comprises: (i) Dr. Michael Min XU and Ms. Xiaojun WANG as executive directors; (ii) Dr. Xiangjun ZHOU, Dr. Yuhong XU, Ms. Ting ZHAI and Mr. Hongkai LI as non-executive directors; and (iii) Dr. Jiansun ZHANG, Dr. Yangyang CHEN and Ms. Xinpeng FAN as independent non-executive directors.